The Latest

SEARCH BY KEYWORD
BROWSE BY Category
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

New Webinar Series: PRP & BMAC

Client News
June 16, 2021
CELLS, or the “Clinical Evidence Leadership Lecture Series”, is back in a new digital format. Featuring clinician leaders from around the world, these ...
CELLS, or the “Clinical Evidence Leadership Lecture Series”, is back in a new digital format. Featuring clinician leaders from around the world, these concise, evidence-packed series will be made available immediately upon release to all RegenMed subscribers. There are no fees, scheduling hassles, or viewer requirements, just clinically relevant content.The first series, titled PRP & BMAC, will cover protocols, corresponding real-world data, and insightful commentary from "good actor" clinicians and scientists regarding this increasingly important regenerative medicine approaches, whether uses as primary or adjunct therapies. Episode 1: “Intraosseous PRP for Knee OA” will feature Jose Miguel Catalán, M.D. of Palma Mallorca, Spain, and his scientific collaborator, Severiano Dos Anjos, Ph.D. as they cover:The Knee OA pathology at a biological level.Typical challenges with orthobiologic treatments, including intraarticular approaches and PRP variability.Details on Dr. Catalán’s intraosseous technique and approach.Relevant data points and uses for PRP characterization data.A real-world evidence protocol that correlates Dr. Catalan’s early real-world data against long-term patient outcomes.Opportunities for viewers to collaborate in the delivery, assessment, and standardization of this technique with their own patient population.We hope you enjoy the trailer and will update all RegenMed newsletter subscribers when the full episode is available for streaming.For more information on this episode, Dr. Catalán’s Circle, or participating in a future CELLS video, please contact ntierney@rgnmed.com.
See more
Arrow right

Improving Patient Engagement through Competition

Post
June 9, 2021
Poor patient engagement can lead to non-compliance, adverse outcomes and substantial expense. (Lack of medicinal adherence costs the US healthcare system ...
Poor patient engagement can lead to non-compliance, adverse outcomes and substantial expense. (Lack of medicinal adherence costs the US healthcare system over $250 billion per year.) Those same issues affect research, whereby patients are too unmotivated, over-burdened, or both, to report upon their long term progress. And yet obtaining these results consistently and across a heterogenous population of patients is key to the success of generating real world evidence, which is increasingly used by manufacturers, institutions and private clinics to support safety and efficacy of their products and protocols.The stationary bicycle company Peloton has become a health and wellness success story based on engaging its customer base. It boasts over 4.4 million members on its digital platform, but even more interestingly, has doubled its per subscriber monthly workout totals over the last year. How does Peloton get its members off couches and onto bikes? By fostering among them an ongoing sense of competition.Member data, such as kilojoules of generated energy, is consistently tracked by the Peloton platform and presented back to the user. A Peloton “Member” thus regularly and easily quantifies her progress, compares it against pre-established goals as well as against others in the Peloton database. The engagement and results of this “gamification” speak for themselves.Clinicians, researchers and product manufacturers can apply these lessons to their own patient engagement initiatives, by:Choosing simple, effective “patient-accessible” quantification metrics. PROMs are good; surveys based on objective, sensor-based data are better.Weighing benefits against burdens from the patient’s perspective. Consider the length and complexity of the survey related to the perceived value of its metric.Providing immediate, quantitative feedback upon patient completion. Provide context, provide goals and if relevant, even comparison “competition” against others within their cohort.These and similar elements will greatly improve patient engagement, and are at the heart of any Circle we manage.
See more
Arrow right

Healthcare Data For The Busy Clinician

Article
June 1, 2021
This paper argues that modern systems technology, supporting global collaboration among providers and industry, can generate clinical and commercial value for patients, clinicians, and industry alike.
TABLE OF CONTENTS‍‍INTRODUCTION The Status Quo The Importance of Real-World Evidence The FutureTHE CHALLENGES Burden Lack of Incentive Limited Access To Expertise The Isolation of a Practitioner Data Access IRB/MEC Requirements Complexity of Technical Systems Barriers To Publication The Provider - Industry “Divide”A PROPOSED APPROACH Fielding The Team “Small Data”, Not “Big Data” Reliable, Accessible Data The Power of Peer-to-Peer Collaboration Burden and Cost Ethical Provider-Industry Cooperation Turnkey, Integrated SolutionCONCLUSIONAbstractA critical step in helping fix “broken healthcare” is re-thinking healthcare data, an important component of which is real world data. These data are found, by definition, at the locus of clinician-patient interactions and patient outcomes assessments.Such real-world data are, in turn, the foundation of real-world evidence, the clinical, scientific, and commercial value of which are widely recognized.Real-world data – the building blocks of real-world evidence – are not to be found in lengthy expensive RCT’s. The severe inclusionary/exclusionary criteria, limited population sizes, length, cost, product specificity and limited data access of those trials result in the antithesis of RWE. However, capturing real-world data in the busy provider environment, and converting it into clinically and statistically significant real-world evidence, pose a number of challenges.This paper argues that modern systems technology, supporting global collaboration among providers and industry, can generate clinical and commercial value for patients, clinicians, and industry alike. Importantly, it can do so in a minimally burdensome, cost-effective manner with excellent user experience.IntroductionThe Status QuoIt is commonly stated that “healthcare is broken”. Costs are rising far faster than most broad health metrics. Physicians are burnt out; patients are frustrated and confused; clinical translation of promising scientific advances is thwarted by lengthy and expensive regulatory hurdles. The two most important groups in the delivery of safe and efficacious healthcare – product manufacturers and providers – find it increasingly difficult to communicate with each other. Healthcare is broken in no small part because healthcare data is “broken”. This is ironic because the world is awash in healthcare data – claims, EMR’s, registries, biosensors, omics analyses, images, thousands of annual conference presentations, and thousands more of journal articles.This enormous amount of data has made clinical decision-making more burdensome, expensive, and confusing. It is far from clear that it has made it better. And of course, this healthcare information “overload” will only accelerate in years to come.The Importance of Real-World EvidenceRWE is a critical component of regulatory compliance, clinical decision-support, value-based medicine, product development/improvement and patient engagement and evidence-based marketing.RWE is not only important support for traditional RCT’s; in many cases it is recognized as superior. It is the basis of many accepted study formats, including pragmatic, n of 1, observational, quality improvement and registries.The power of RWE lies in its large patient population potential, data deriving from everyday clinical interventions, and long-term outcomes capture. Unlike the vast majority of RCT’s sponsored by well-capitalized product companies, RWE is based on data with a much higher degree of clinical relevance.Of course, data are critical for the practitioner. But only the right data, at the right time and with specific clinical relevance. Moreover, data are of little use if they are not easily accessible and verifiable by busy clinicians.The FutureOther segments in the economy are able successfully to define, aggregate and utilize data to achieve their specific objectives. For this to happen in healthcare, the following are needed:All healthcare constituencies must recognize the power of real-world data and evidence. The evidence which is inherent in each patient-clinician interaction, but which is often ignored.Clinical thought leaders should exercise their influence by identifying and disseminating the key clinical/scientific questions facing everyday practitioners in their respective fields.Busy clinicians need to be incentivized to capture real-world data.Modern, cost-effective systems and user experience should be implemented which ensure minimum clinical burden in that capture.The institutional and national boundaries preventing genuine and ongoing collaboration among clinicians with similar practices must be overcome.Communications channels between industry and providers must be created enabling the meaningful and sustained exchange of value generated by real-world evidence.Contemporary, targeted publication modalities – including digital and secure social media formats – must be utilized to maximize the clinical education and training potential arising from real-world evidence.This is what clinically useful healthcare data in the 21st century should look like.The ChallengesImpediments to developing and generating value from real-world evidence include the following:BurdenHealthcare delivery models, combined with shrinking reimbursement, impose a large administrative burden on providers. They leave less time for patient care, let alone the capture and analysis of real-world data.Thus, the “real world” is the busy, already over-burdened environment of clinical interventions. It is the unreported outcomes.Lack of IncentivesMany well-intentioned practitioners spend their evenings entering clinical data into medical society of industry sponsored “registries”. They are rarely compensated, financially or professionally, for these efforts. Moreover, those registries typically sharply curtail data access and ownership, and the ability to generate reports specific to a pressing clinical question is difficult if not impossible.Limited Access To ExpertiseThe first step to generating real-world evidence is asking a few “right” questions for a specific indication/treatment protocol. For the busy clinician, this is often not easy.Medical science is advancing ever more rapidly, and is increasingly complex. Much of what was taught in medical school is out-of-date; nor are CME courses particularly helpful. Clinical medicine is becoming hyper-specialized while, at the same time, there is greater recognition of the systemic nature of pathologies as well as treatments.The enormous volume of journal articles, conference presentations and webinars – often inconsistent in their conclusions – have led to information overload and confusion.The Isolation of a PractitionerEven in large academic medical centers, the busy clinician is more isolated from her peers than ever before. Annual society conferences are a welcome respite, but are a far cry from meaningful, sustained collaboration on clinical issues. This isolation has repercussions not only in terms of “burn-out”, but in terms of education, training, and professional advancement.Data AccessAnonymized (non-PHI) data security, ownership, control, and access are important considerations for real-world evidence. There is often a lack of clarity regarding these issues for the practitioner – together with his patients the primary source of real-world data.IRB/MEC RequirementsReal-world evidence derives by definition from clinician-patient interactions. Provider policies, journal requirements and/or the desire of the practitioners herself may require the involvement of an Institutional Review Board or Medical Ethics Committee. For clinicians collaborating across institutional borders, and developing RWE in a multi-center context, a reputable commercial IRB may be required.This can pose a severe administrative and financial burden.Complexity of Technical SystemsSoftware is supposed to make things easier. In healthcare, IT systems are often expensive, complex and involve poor user experience. In addition, there is generally poor communication among various healthcare software systems, even when used by the same provider. Barriers To PublicationTimely access to relevant evidence is an essential component of its value. Unfortunately, for today’s busy clinician, evidence is often delayed, inaccessible, irrelevant, and/or unverifiable. Paradoxically, the proliferation of articles, societies and other information sources often compounds rather than addresses the problem.The Provider - Industry “Divide”In principle, cooperation between industry and providers should lead to greater efficiencies in achieving and clinically translating medical advances. In practice, however, well-intentioned regulations and institutional policies often thwart that cooperation.‍A Proposed ApproachFielding The TeamSafe and efficacious healthcare delivery obviously depends heavily on “data”. Those data are required in many different contexts. Here, we are discussing only a single but critical context: providing meaningful clinical decision support to the busy clinician through real-world evidence.As suggested above, “simplifying” the generation of and access to such data is a multifaceted challenge. Addressing this task, as is true for any complex task, begins with assembling and coordinating the right “team”. Here, that team comprises thought leaders, practicing clinicians, industry, medical societies, and patients.Of course, each of these “players” has its own interests and constraints. However, they all benefit in multiple ways from the development of real-world evidence. There is a mutual incentive to work together.“Small Data”, Not “Big Data”Clinical context is all-important for the development of real-world evidence, as well as for achieving its intended purpose. The clinician must exercise her professional judgment in the context of a specific patient, a specific complaint, a specific number of available treatment protocols. Moreover, she must often do so in a relatively short amount of time, which means limited information.The answer is not more data. Rather it is the right data most relevant to that particular clinical encounter and intervention.Reliable, Accessible DataThe clinician and his patient are entitled to diagnoses and treatments which are based on verifiable data – data which are clinically and statistically significant. If such evidence in fact already exists based on relevant, independent RCT’s, that is of course desirable. But most “standards of care” have no or poor quality of evidentiary support.Moreover, medical science is advancing at an accelerated pace. A busy clinician may see ten or more patients each day. He has far too little time to examine the latest potentially relevant literature. Also, the full data behind most RCT’s is rarely easily or fully accessible.This is the value of real-world evidence. It can be delivered in a timely, accessible, and clinically relevant manner.The Power of Peer-to-Peer CollaborationMedicine is increasingly specialized; clinicians are often isolated. This need not be the case, however. Whatever the clinician’s particular field and practice environment, there are many hundreds of peers around the world facing the same issues, in similar environments.Moreover, there are many clinical and scientific thought-leaders ready to assist in defining the right real-world data questions to ask, and in deriving clinically useful correlations from the resulting datasets.Other sectors of the economy are able to achieve and exploit network effects much more successfully than healthcare. The concept of real-world evidence is a powerful opportunity for clinicians, industry, and patients to collaborate in a manner achieving real value for all.Modern technology allows the individual clinician to benefit from the experience of peers and experts around the world in a secure and productive way.Burden and CostHere again, it is useful to compare healthcare with other complex sectors of the economy (finance, semiconductors, telecommunications, space travel, information technology). Those sectors routinely advance their scientific foundations and improve user experience, while driving down costs.Modern systems allow the collection and aggregation of, and value generation from, real-world evidence in a cost effective, minimally burdensome manner.Ethical Provider-Industry CooperationReal-world evidence potentially represents a legitimate and powerful exchange of value among three major healthcare constituencies – providers, patients, and industry. That value includes:Support for clinician decision-makingReimbursement (value-based medicine)Legal/regulatory submissions/complianceProduct development/improvementNew indications ResearchPatient engagementJournal articles, conference presentationsExpanded thought leader influenceEducation and trainingDeeper clinical customer engagementA major “safe harbor” for industry interaction with and support of providers is the investigator-initiated development of real-world evidence. ‍Turnkey, Integrated SolutionThe value of real-world evidence will not be attained through piecemeal, uncoordinated solutions. Rather, the busy practitioner needs a turnkey approach which integrates the foregoing elements in an efficient, cost-effective, and burden-free manner.Modern technology and processes make this fully achievable in many sectors of the economy. It is equally possible in healthcare as well.ConclusionAlbert Einstein famously said, “make everything as simple as possible, but not simpler.” In healthcare as elsewhere, it is more difficult to achieve simplicity than complexity. Some data, such as dealing with over 10,000 CPT codes for reimbursement, are unavoidably burdensome and complex. Unfortunately, they are also often clinically unhelpful.Conversely, the busy clinician usually requires only a few critical pieces of evidence to augment his professional judgment in developing a treatment protocol with safe, predictable, and effective outcomes. The elements needed to generate that evidence are not complex in principle:Identify a limited number of specific correlations (evidence) which will provide the most valuable clinical decision support for a given indication and patient cohort.Identify the right question and answer formats, including long-term outcomes, most likely to prove/disprove the posited correlations.Collect, aggregate, and analyze those real-world data inherent in one’s everyday practice which are most likely to prove/disprove the posited correlations, and may also uncover “serendipitous” ones.Iterate and improve based on the real-world data constantly generated through one’s clinical activities.Collaborate closely with peers, domain experts and industry in implementing each of the foregoing steps.The broad technical advances in the 21st century enable the busiest solo practitioner to develop real-world evidence which will make a material difference for her practice, her professional advancement, and her patients. The value for larger provider systems and industry is even more profound.For more information, please contact us.
See more
Arrow right
Nothing was found. Please use a single word for precise results.
Stay Informed.
Subscribe for our newsletter
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.